BYD-AUTO
21.11.2023 02:00:47 CET | Business Wire | Press release
BYD, the world’s leading manufacturer of new energy vehicles, showcased its full lineup of vehicles at the 21st Guangzhou International Automobile Exhibition from November 17th to 26th. BYD featured the global debut of the e⁴ concept car, the release of the Supercar Platform, and the unveiling of the new pure electric SUV—the BYD Sea Lion 07 EV*.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231120172380/en/
New concept car of Yangwang (Photo: Business Wire)
Yangwang Unveiled a New e⁴ Concept Car and Supercar Platform
BYD's premium sub-brand Yangwang dazzled with the debut of its latest e⁴ concept car, supercar platform, and brought U8 and U9 to the auto show. The e⁴ concept car by Yangwang lacked traditional steering gear and braking mechanisms. It employed a three-in-one technology for driving, braking, and steering, eliminating the need for conventional mechanical systems. Earlier this year, Yangwang introduced the exclusive Yangwang Architecture for high-end new energy vehicles. The Supercar Platform under this architecture made its official debut, marking Yangwang's transition from the wilderness to the racetrack with cutting-edge technology. At the exhibition, the interior of the Yangwang U9 was unveiled for the first time, showcasing a cockpit that exuded both technological sophistication and sportiness.
Sea Lion 07 EV*: A New Member of the BYD Ocean Series
BYD Ocean Series unveiled its first mid-sized pure electric SUV, the Sea Lion 07 EV*, at the exhibition. Embracing the 'Ocean Aesthetics' design philosophy, it utilized rear-wheel/four-wheel drive architecture, equipped with CTB technology and iTAC intelligent torque control technology. Additionally, it featured front double-wishbone and rear five-link independent suspension, along with the BYD DiSus Intelligent Body Control System. Currently, the Ocean Series boasts several popular models such as the Dolphin, Seal, establishing a robust Ocean Series IP. In the future, the Ocean Series would consolidate SUV models under the intellectual property of Sea Lion* and sedan models under the intellectual property of Seal.
Denza D9 PREMIER (inaugural edition with four seats) Showcased its Intelligent Configurations
Denza, another high-end sub-brand under BYD's diversified brand matrix, presented the D9 PREMIER (inaugural edition with four seats) along with several cutting-edge technologies. The exterior of D9 PREMIER (inaugural edition with four seats) adopted a galaxy dual-tone body, and the interior featured the application of intangible cultural heritage gilding techniques. The cabin was equipped with 22 DEVIALET audio speakers and a premier intelligent customized cockpit, including an 8-inch armrest screen.
In December, high-speed NOA (Navigate on Autopilot) will be rolled out to consumers, followed by the gradual release of urban NOA in Q1 of next year. High-speed NOA-enabled vehicles will be delivered to consumers in December. Additionally, features such as Sentry Mode, Light Map Mode, and Commute Mode will progressively roll out next year.
FANGCHENGBAO and the Stunning BAO 5
BYD's professional personalized sub-brand FANGCHENGBAO also brought its BAO 5 to the exhibition. The BAO 5, which was just launched last week, positioned itself as a "Super Hybrid Hardcore SUV" starting at 289,800 RMB and was equipped with BYD's core technologies such as DMO and DiSus-P. BAO 5 used the ultra-safe blade battery, which adopted a 5-layer protection structure and was shielded by a ring-type double protection system.
BYD had a total of 4 booths at the 21st Guangzhou International Automobile Exhibition, which continued until November 26th. Various of BYD’s hardcore technologies, including the Dual Mode Off-road (DMO) Super Hybrid Platform, BYD DiSus Intelligent Body Control System, and e⁴ Platform also made appearances by some display platforms at this exhibition. BYD demonstrated its pioneer technology and leading advancements, contributing to helping cool the earth by 1℃.
(The product name with the "*" mark in this press release is a translation from the Chinese product name and is currently only applicable for the expressions of models launched in China.)
About BYD
BYD is a multinational high-tech company devoted to leveraging technological innovations for a better life. Founded in 1995 as a rechargeable battery maker, BYD now boasts a diverse business scope covering automobiles, rail transit, new energy, and electronics, with over 30 industrial parks in China, the United States, Canada, Japan, Brazil, Hungary, and India. From energy generation and storage to its applications, BYD is dedicated to providing zero-emission energy solutions that reduce global reliance on fossil fuels. Its new energy vehicle footprint now covers 6 continents, over 70 countries and regions, and more than 400 cities. Listed in both Hong Kong and Shenzhen Stock Exchanges, the company is known to be a Fortune Global 500 enterprise that furnishes innovations in pursuit of a greener world.
For more information, please visit www.bydglobal.com.
About BYD Auto
Founded in 2003, BYD Auto is the automotive subsidiary of BYD, a multinational high-tech company devoted to leveraging technological innovations for a better life. Aiming to accelerate the green transition of the global transportation sector, BYD Auto focuses on developing pure electric and plug-in hybrid vehicles. The company has mastered the core technologies of the entire industrial chain of new energy vehicles, such as batteries, electric motors, and electronic controllers. It has witnessed in recent years significant technological advancements, including the Blade Battery, DM-i Super Hybrid Technology, e Platform 3.0, CTB Technology, e⁴ Platform, BYD DiSus Intelligent Body Control System, and DMO super hybrid system. The company is the world's first carmaker to stop the production of fossil-fueled vehicles on the EV shift and has remained top of new energy passenger vehicle sales in China for 10 years in a row.
For more information, please visit www.byd.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231120172380/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
